Bicara Therapeutics, Inc

Bicara Therapeutics, Inc. was founded in 2020 and headquartered in Cambridge, Massachusetts, USA. Bicara Therapeutics develops dual action cancer therapy, combining targeted therapy with tumor regulators to enhance efficacy.

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/bicara.html

Bicara Therapeutics, Inc

Bicara Therapeutics is a biotechnology start-up company at the clinical stage, focusing on the development of double effect biological agents. The company is developing bifunctional antibodies, aiming to deliver immune regulation payloads directly to tumor microenvironment, help cancer patients improve immune cell activity, and may provide long-term curative effects. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/bicara.html

Bicara Therapeutics' experienced leadership and clinical development team in Cambridge have a deep relationship with the world's top cancer centers, and have rich experience in company construction and drug development. In order to realize the common vision of providing first-rate and meaningful treatment for cancer patients, Bicara Therapeutics cooperates with skilled protein engineers, immunologists and CMC experts. They have the experience of constructing highly complex molecules and the record of developing FDA approved drugs. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/bicara.html

Bicara Therapeutics' double effect antibody combines the accuracy of tumor targeting antibody that has been fully verified with the powerful function of tumor microenvironment (TME) regulator, which can produce synergistic and lasting effects at the tumor site. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/bicara.html

Cancer deploys many defense mechanisms to evade the immune system and treat them. One of the most effective escape strategies is to manipulate the complex biochemistry of the tumor surrounding ecosystem (tumor microenvironment) to suppress immune cells that would otherwise attack cancer. Targeted therapy may initially overcome cancer defense, but cancer will quickly develop drug resistance and evolve escape mechanisms. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/bicara.html

Bicara Therapeutics uses its platform to design bifunctional molecules to precisely target tumors and provide tumor regulatory payloads, thereby minimizing side effects. Effectively delivering immune regulation payloads to tumors also means that the drug dosage required for anti-tumor effect is low, thus reducing the toxicity to healthy tissues in other parts of the body. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/bicara.html

Bicara Therapeutics has more than just a platform: the company has a series of promising bifunctional antibodies and other biological agents for the treatment of solid tumors, including leading projects that have entered the clinic. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/bicara.html

Bicara led project: BCA101- First class EGFR/TGF β- Trap bifunctional antibody The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/bicara.html

Epidermal growth factor receptor (EGFR) is a protein expressed on the surface of many tumor types, and is one of the most widely verified tumor related antigens. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/bicara.html

Monoclonal antibodies against EGFR can inhibit the proliferation of tumor cells driven by EGFR, and limit the growth and metastasis of tumors. Inhibition of EGFR alone is not enough to achieve a lasting therapeutic response. Our solution: simultaneously inhibit EGFR and TGF- β—— A signaling molecule that promotes tumor growth in the presence of EGFR and plays a key role in inhibiting immune responses in the tumor microenvironment. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/bicara.html

Therefore, the leading project of Bicara is a bifunctional antibody with dual functions, which can not only inhibit EGFR, but also directly disable TGF at the tumor site- β。 In this way, Bicara hopes to achieve excellent anti-tumor efficacy through the improved therapeutic window.

Financing Encyclopedia of Bicara Therapeutics, Inc

In March 2021, Bicara Therapeutics, Inc. completed the seed round financing of 40 million dollars, with exclusive participation of Biocon.

In March 2023, Bicara Therapeutics, Inc RA Capital Management And the $108 million round B financing led by Red Tree Venture Capital, Eight Roads Ventures F-Prime Capital 、 Invus , Omega Funds, etc.

In December 2023, Bicara Therapeutics, Inc. completed the work of Braidwell, The Rise Fund and TPG Round C financing of $165 million led by Eight Roads Ventures F-Prime Capital 、 Invus 、 RA Capital Management Wait for the follow-up.

Bicara Therapeutics, Inc. US equity investment

Unlisted company ， Company official website , waiting for Bicara Therapeutics, Inc IPO Listing.